3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Anaveon AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) ANV600, ANV600 + pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Anaveon AG | 63 | 2024-07-01 | 2026-07-10 |
| ACT-TIL and ANV419 for Advanced Melanoma. Combination of Tumor-infiltrating lymphocyte transfer with ANV419 - Advanced Melanoma | Phase 1 | Active not recruiting | University Hospital, Basel, Switzerland | 10 | 2023-06-21 | 2026-02-27 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. ANV419, Ipilimumab - Advanced Solid Tumor, Adult Disease | Phase 1 | Completed | Anaveon AG | 55 | 2021-05-25 | 2024-11-08 |
Disease (3) · Neoplasms (3) · Recurrence (2) · Hematologic Diseases (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1)
Dexamethasone (1) · Ipilimumab (1) · Lenalidomide (1) · daratumumab (1) · pembrolizumab (1)
Spain (4) · Switzerland (4) · France (3) · Germany (3) · United States (2) · Belgium (1) · Denmark (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Eduard Gasal, MD (3)
2023 (2)